Immuneering updated Phase IIa data showing its oral MEK inhibitor atebimetinib, given with modified gemcitabine/nab‑paclitaxel chemotherapy, was associated with a 64% overall survival rate at 12 months in first-line pancreatic cancer. The company reported median progression‑free survival and stated the study’s median OS remained unreached at data cut. Immuneering is preparing a pivotal Phase III trial slated to start mid‑2026 after aligning trial design with the FDA. Management emphasized PFS as a surrogate that supports the OS signal and plans a randomized pivotal study comparing atebimetinib plus chemo against standard care in roughly 510 patients with OS as the primary endpoint. The data and planned Phase III will be watched closely given pancreatic cancer’s high unmet need and the difficulty of improving survival with new targeted agents.